.png)
.png)
.png)
Total amount raised
$1.6B
Latest funding date
2025-09-16
Location
PharmEasy has successfully raised funds through 15 rounds, with the latest being debt financing led by 360 ONE Asset. The platform connects users to local pharmacies and labs, offering medicine delivery and diagnostic services.
With 57 investors backing its growth, including Micro Labs and Bennett Coleman and Co Ltd, PharmEasy continues to expand its reach in the healthcare sector. Keep reading to explore the intricacies of PharmEasy's fundraising journey and the investors supporting this innovative platform.
PharmEasy has raised funds across multiple rounds, backed by investors including Bessemer Venture Partners, Temasek, Prosus Ventures, TPG Growth, Tiger Global, 360 ONE Asset, and MEMG Family Office.
Keep reading to explore PharmEasy's complete fundraising history.
What Is PharmEasy?
PharmEasy (operated by API Holdings) is India's largest digital healthcare platform, based in Mumbai. Founded in 2015, it offers medicine delivery, diagnostics, and telehealth services, serving millions of consumers across India.
How Much Funding Has PharmEasy Raised?
- Series A
- Amount Raised: USD 5,000,000
- Date: December 2015
- Lead Investors: Bessemer Venture Partners, Orios Venture Partners
- Series B
- Amount Raised: USD 17,000,000
- Date: March 2017
- Lead Investors: Bessemer Venture Partners
- Participants: Orios Venture Partners, Aarin Capital
- Series C (Tranche 1)
- Amount Raised: USD 30,000,000
- Date: February 2018
- Lead Investors: Bessemer Venture Partners
- Participants: Orios Venture Partners, Manipal Education and Medical Group (MEMG)
- Venture Debt
- Amount Raised: USD 5,500,000
- Date: September 2018
- Lead Investors: InnoVen Capital
- Series C (Tranche 2)
- Amount Raised: USD 50,000,000
- Date: September 2018
- Lead Investors: Eight Roads Ventures India, F-Prime Capital, Fundamentum
- Participants: Bessemer Venture Partners, Think Investments, Ascent Health & Wellness Solutions, Orios Venture Partners
- Series D
- Amount Raised: USD 220,000,000
- Date: November 2019
- Lead Investors: Temasek Holdings
- Participants: Bessemer Venture Partners, Eight Roads Ventures, CDPQ, LGT Group, Fundamentum, Orios Venture Partners, KB Financial Group
- Series E
- Amount Raised: USD 350,000,000
- Date: April 2021
- Lead Investors: Prosus Ventures, TPG Growth
- Participants: Eight Roads Ventures, Temasek, CDPQ, Think Investments, Lightrock
- Secondary Market
- Amount Raised: USD 20,000,000
- Date: June 2021
- Lead Investors: B Capital
- Series F
- Amount Raised: USD 500,000,000
- Date: July 2021
- Lead Investors: Undisclosed
- Participants: Tiger Global, Temasek, Orios Venture Partners, B Capital, TPG Growth, Kotak Private Equity, Think Investments, Prosus Ventures
- Pre-IPO Round
- Amount Raised: USD 204,000,000 (primary); up to ~USD 344,000,000 including secondary
- Date: October 2021
- Lead Investors: Undisclosed
- Participants: Amansa Capital, ApaH Capital, Janus Henderson, OrbiMed, Steadview Capital, ADQ, Neuberger Berman
- Debt Financing
- Amount Raised: Undisclosed
- Date: November 2022
- Lead Investors: EvolutionX Debt Capital
- Private Equity (Rights Issue)
- Amount Raised: Undisclosed (part of ~USD 417,000,000 rights issue)
- Date: January 2024
- Lead Investors: Undisclosed
- Participants: Prosus (Naspers), Temasek Holdings
- Private Equity
- Amount Raised: USD 216,000,000
- Date: April 2024
- Lead Investors: MEMG Family Office (Ranjan Pai / Manipal Group)
- Participants: Prosus, Temasek, 360 ONE Portfolios, CDPQ, Goldman Sachs, EvolutionX Debt Capital, WSSS Investments
- Debt Financing
- Amount Raised: USD 193,000,000 (INR 1,700 crore)
- Date: September 16, 2025
- Lead Investors: 360 ONE Asset
- Participants: Micro Labs Limited, MVS Ventures, Bennett Coleman, Alkram Ventures, Kyrush Investments, Medley Pharmaceuticals, Mahalaxmi Trust
Total Amount Raised: At least $1.6B based on disclosed funding (some rounds partially or fully undisclosed).
Key Investors
- 360 ONE Asset
- Details: Lead investor in the September 2025 debt round (INR 1,231 crore of INR 1,700 crore total). Also participated in the April 2024 equity round. A major Indian wealth and asset management firm.
- MEMG Family Office (Manipal Group / Ranjan Pai)
- Details: Led the April 2024 private equity round of $216M at a $710M post-money valuation, committing INR 800 crore. Stepped in as a key backer through a period of significant valuation decline.
- Temasek Holdings
- Details: Long-term backer, led the Series D round ($220M, November 2019) and participated in multiple subsequent rounds including Series E, Series F, and the April 2024 private equity round.
- Prosus Ventures (Naspers)
- Details: Co-led the Series E ($350M, April 2021) alongside TPG Growth. Also participated in the Series F, pre-IPO round, and April 2024 rights issue.
- Bessemer Venture Partners
- Details: Early-stage backer, invested from Series A (2015) through Series D (2019). Led the Series B and Series C rounds, anchoring PharmEasy's early growth.
- EvolutionX Debt Capital
- Details: Provided debt financing in November 2022 (undisclosed amount). A debt capital platform founded by DBS and Temasek, focused on growth-stage companies in Asia.
What's Next for PharmEasy?
PharmEasy is focused on operational efficiency and profitability after years of aggressive expansion and subsequent valuation corrections. With its debt restructuring via the September 2025 round, the company is working to repay the Goldman Sachs loan and stabilize its financial position. Backed by strategic investors including Manipal Group and 360 ONE, PharmEasy aims to strengthen its core medicine delivery and diagnostics business across India.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data. Sign up for free today.
